Distribution of FK 506 in plasma lipoproteins in transplant patients.

Abstract

FK 506, a powerful, new immunosuppressive agent, is currently undergoing clinical trials in transplant patients. Like cyclosporine (CyA), FK 506 suppresses interleukin-2 production and receptor expression on T cells.1,2 Additionally, both FK 506 and CyA are highly lipophilic.3 CyA is mainly transported by lipoproteins in plasma.4 The objective of the present study is to characterize the distribution of FK 506 in various plasma components.